How to Buy Veracyte Stock
Veracyte Inc
Veracyte, Inc. operates as a global diagnostics company, specializing in the development and commercialization of advanced genomic tests.
Veracyte stock last closed at $51.29, up 0.73% from the previous day, and has increased 91.67% in one year. It has overperformed other stocks in the Biotechnology industry by 1.63 percentage points. Veracyte stock is currently +126.85% from its 52-week low of $22.61, and -2.79% from its 52-week high of $52.76.
As of Jun 17, 2026, there are 79.79M VCYT shares outstanding. The market cap of VCYT is $4.09B. In the past 24 hours, 1.23M VCYT shares were traded.
How to Buy Veracyte Stock
Not sure how to invest in Veracyte stock? Here's how.
- Choose where to buy Veracyte stock: You need to pick a stock brokerage, but don't worry - we've analyzed dozens of online stock brokerages and apps to help you figure out where to buy Veracyte stock.
- Create a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Deposit money your brokerage account: Select your payment method and add your information.
- Research Veracyte stock: The Veracyte ticker symbol is VCYT. Is Veracyte stock a good investment? Should you buy shares of VCYT? How do VCYT's underlying business fundamentals look? Do top analysts think Veracyte is a good buy? Why has VCYT's stock price moved recently? (Hint: Our stock research website can help you figure out if VCYT is a good stock to buy).
- Place your VCYT buy order: Decide if you will purchase VCYT shares at the current market price or use a limit order to purchase VCYT stock at a particular price.
- Keep an eye on your VCYT position: Create a watchlist to get the latest news on your new investment in Veracyte stock.
Step 1: Choose where to buy Veracyte stock
You will need a brokerage account in order to access the NASDAQ market and buy VCYT stock.
Our favorite brokerage: eToro
In our opinion, eToro is the best brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to world markets: From Technology to Financial Services, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro boasts a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of shares by opening an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create a brokerage account
Now that you've chosen your brokerage, it's time to fill out some personal information so you can invest in VCYT today.
How to Set Up a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal info to start your new brokerage account.
- Send your info by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit money your brokerage account
Now that you've finished signing up on the best stock trading app, you need to deposit funds:
Watch the video below if you need help transferring money into your new brokerage account.
Step 4: Research Veracyte stock
After you have figured out the best place to buy Veracyte stock, it's critical to research their stock prior to investing, so you truly wrap your head around the risk and opportunity.
Veracyte shares at a glance
Fundamentals of Veracyte
WallStreetZen was designed to help average investors perform more accurate fundamental analysis quickly.
You can view all of the due diligence checks on VCYT's stock page.
How is VCYT stock valued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge VCYT's intrinsic value.
Using relative valuations ratios:
- VCYT could be overvalued based on its P/E ratio of 46.21x, relative to Biotechnology industry P/E ratio of 14.91x
- VCYT could be undervalued based on its P/B ratio of 3.04x, relative to Biotechnology industry P/B ratio of 4.94x
- VCYT could be overvalued based on its PEG ratio of 9.84x
You can do additional valuation research on VCYT's stock here.
VCYT Financial Overview
Signs that VCYT is financially healthy:
- There are more short-term assets than long-term liabilities on the VCYT balance sheet.
- VCYT's operating cash flow of $166.16M allows it to safely service it's debt of $39.33M.
- VCYT has a low debt to equity ratio of 0.07.
- There are more short-term assets than short-term liabilities on the VCYT balance sheet.
- VCYT profit margin has gone up from 7.1% to 16.2% in the past year.
- VCYT earnings of $90.75M is not sufficient to cover its interest payments.
Signs that VCYT is not financially healthy:
- Total VCYT debt is higher than 5 years ago, relative to shareholder equity.
Do analysts think it's a good time to buy VCYT stock
Out of 6 Equities analysts who give ratings on VCYT, the consensus analyst rating on Veracyte is a Buy
Please note that analyst forecasts are not stock recommendations, nor are they financial advice.
Most Recent VCYT Analyst Upgrades/Downgrades
Tejas Savant, a bottom 5% analyst from Morgan Stanley maintains VCYT with a strong sell rating and lowers their VCYT price target from $48.00 to $37.00, on Mar 6, 2026.
You can dig deeper into what analysts are saying on the Veracyte stock forecast page.
VCYT Technical Indicators
VCYT Earnings
Last year, VCYT earnings were $88.01M. During the past 1 years, VCYT's earnings have grown by 158.14% per year. This was faster than the Biotechnology industry average of 12.59%.
Last year, VCYT revenue was $541.74M. In the past five year, VCYT's revenue has increased by 34.5% per year. This was faster than the Biotechnology industry average of 32.15%.
You can analyze VCYT's earnings and revenue performance here.
Latest Insiders Trades at VCYT
In the past year, insiders at VCYT have sold more shares than they have bought.
Rebecca Chambers, Chief Financial Officer of VCYT, was the latest VCYT insider to sell. They sold $78,854.40 worth of VCYT shares on Jun 4, 2026.
Get more info about who owns VCYT shares here.
Can I rely on VCYT as an income stream?
No, Veracyte doesn't provide an income stream by paying out dividends.
What others are saying about VCYT
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Place your VCYT buy order
There are two primary options:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are usually fine for most investors. - Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
If you want to be certain you're buying or selling at a given price limit, use a limit order.
Hit the Open Trade button and eToro will place the order.
If you need more help buying stocks on eToro, watch the helpful video below:
Step 6: Keep an eye on your VCYT position
Now that you own some shares in VCYT, you'll want to stay up-to-date on your new shares.
Put VCYT on a watchlist to track the most important metrics related to your VCYT stock.
VCYT Feed
How to Buy Stock in Veracyte
To summarize, here are the 6 steps you need to take to buy Veracyte stock right now:
- Choose where to buy Veracyte stock
- Create a brokerage account
- Deposit money your brokerage account
- Research Veracyte stock
- Place your VCYT buy order
- Keep an eye on your VCYT position
If you need a brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to keep an eye on your investment in Veracyte, create a watchlist on WallStreetZen today.
Related Stock Buying Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.